Skip to main content

Table 4 Univariate logistic regression for enrolment and CSF Aβ1–42 positivity in whole sample and stratified by recruitment setting

From: Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings

Sample size

Total

 

Toulouse Registry

ALFA Study

Generation Scotland

pilotHO.nl

n = 2595

n = 324

n = 158

n = 64

n = 271

n = 124

n = 1947

n = 61

n = 220

n = 75

Outcome

Enrolment*

CSF Aβ +ve^

Enrolment*

CSF Aβ +ve^

Enrolment*

CSF Aβ +ve^

Enrolment*

CSF Aβ +ve^

Enrolment*

CSF Aβ +ve^

Aged over 70 years Old

0.97 (0.95–0.99)

1.06 (1.02–1.10)

0.99 (0.94–1.03)

1.10 (1.01–1.20)

0.99 (0.95–1.03)

1.01 (0.94–1.08)

0.97 (0.93–1.01)

1.23 (1.08–1.45)

0.96 (0.93–1.00)

1.03 (0.97–1.11)

Male

1.56 (1.19–2.04)

1.28 (0.81–2.04)

1.17 (0.58–2.42)

0.30 (0.08–0.96)

2.03 (1.24–3.35)

2.03 (0.92–4.60)

1.81 (1.11–3.01)

1.35 (0.47–4.08)

1.13 (0.66–1.94)

2.01 (0.77–5.36)

Highly educated

1.64 (1.23–2.17)

0.89 (0.56–1.42)

1.44 (0.69–2.98)

0.72 (0.25–2.13)

1.42 (0.87–2.31)

1.10 (0.50–2.39)

2.20 (1.34–3.59)

0.66 (0.22–1.88)

1.33 (0.67–2.67)

0.75 (0.24–2.51)

APOE ɛ4 genotype

0.95 (0.70–1.28)

2.99 (1.81–4.94)

NA

6.42 (1.93–24.1)

0.68 (0.41–1.10)

1.72 (0.79–3.86)

1.37 (0.84–2.25)

7.20 (2.2–28.77)

0.92 (0.49–1.72)

3.34 (1.22–9.48)

Family history of Dementia

1.66 (1.19–2.31)

1.58 (0.83–3.00)

1.04 (0.50–2.15)

0.95 (0.31–2.98)

1.12 (0.38–3.23)

NA#

2.95 (1.73–4.91)

2.90 (0.97–8.96)

1.27 (0.73–2.22)

1.94 (0.68–6.09)

Subjective cognitive decline

0.86 (0.58–1.27)

1.51 (0.88–2.61)

0.29 (0.09–0.76)

2.93 (0.67–20.6)

0.79 (0.41–1.55)

1.15 (0.38–3.22)

NA

NA

1.16 (0.62–2.15)

1.73 (0.62–4.79)

Low memory score

0.84 (0.60–1.17)

1.47 (0.82–2.61)

0.63 (0.21–1.87)

18.90 (2.87–377)

0.95 (0.56–1.64)

1.29 (0.55–2.96)

0.78 (0.44–1.31)

0.95 (0.28–3.02)

0.91 (0.29–2.83)

0.58 (0.03–4.98)

  1. Odds ratio (95% CI); CSF cerebrospinal fluid. Italics is significant p < 0.05. *Odds ratio for participating baseline/screening visit after invitation. ^Odds ratio for amyloid positivity among those included in EPAD-LCS. #Infinite, not possible to calculate a value